沙库巴曲缬沙坦治疗老年缺血性心肌病导致射血分数降低心力衰竭患者的可行性  

Feasibility of salkubatrovalsartan in the treatment of elderly patients with heart failure with reduced ejection fraction caused by ischemic cardiomyopathy

作　　者：董利洁 陈娜 DONG Lijie;CHEN Na(No.2 Cardiovascular Medicine Department,Xi'an Union Hospital,Xi'an 710199;No.5 Internal Medicine Department,the People's Hospital of Shangzhou District,Shangluo 726000,China)

机构地区：[1]西安工会医院心血管内二科,陕西西安710199 [2]商洛市商州区人民医院内五科,陕西商洛726000

出　　处：《临床医学研究与实践》2024年第14期45-48,61,共5页Clinical Research and Practice

摘　　要：目的分析沙库巴曲缬沙坦治疗老年缺血性心肌病导致射血分数降低心力衰竭(HFrEF)患者的可行性。方法选取我院2020年8月至2022年8月收治的108例缺血性心肌病导致HFrEF患者为研究对象,根据治疗方案将其分为对照组(n=54,贝那普利治疗)和研究组(n=54,沙库巴曲缬沙坦治疗)。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的左心室舒张末期容积(LVEDV)、左心室舒张末期内径(LVEDD)、左心室后壁厚度(LVPW)均降低,左心室射血分数(LVEF)均升高,且研究组优于对照组(P<0.05)。治疗后,两组的N末端B型利钠肽前体(NT-proBNP)、半乳糖凝聚素-3(Gal-3)、可溶性生长刺激表达基因2蛋白(sST2)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、单核细胞趋化蛋白-1(MCP-1)水平均降低,且研究组低于对照组(P<0.05)。研究组治疗3个月内的主要不良心血管事件(MACE)总发生率低于对照组,住院次数、累计住院时间少于对照组(P<0.05)。结论沙库巴曲缬沙坦能够改善缺血性心肌病导致HFrEF患者的心功能、血清指标,降低MACE发生风险,减少住院次数,短期内疗效确切,临床可进一步推广应用。Objective To analyze the feasibility of salkubatrovalsartan in the treatment of elderly patients with heart failure with reduced ejection fraction(HFrEF)caused by ischemic cardiomyopathy.Methods A total of 108 patients with HFrEF caused by ischemic cardiomyopathy admitted in our hospital from August 2020 to August 2022 were selected as the study objects and divided into control group(n=54,treated with benazepril)and study group(n=54,treated with salkubatrovalsartan)according to the treatment plan.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,left ventricular end diastolic volume(LVEDV),left ventricular end diastolic diameter(LVEDD)and left ventricular posterior wall thickness(LVPW)decreased and left ventricular ejection fraction(LVEF)increased in both groups,and those in the study group were better than the control group(P<0.05).After treatment,the levels of N-terminal B-type natriuretic peptide precursor(NT-proBNP),galectin-3(Gal-3),soluble growth stimulation expressed gene 2(sST2),granulocyte-macrophage colony-stimulating factor(GM-CSF)and monocyte chemotactic protein-1(MCP-1)in both groups decreased,and those in the study group were lower than the control group(P<0.05).The total incidence of major adverse cardiovascular events(MACE)in the study group within 3 months of treatment was lower than that in the control group,and the number of hospitalization and the cumulative length of hospitalization were less than those in the control group(P<0.05).Conclusion Salkubatrovalsartan can improve the cardiac function and serum indexes of patients with HFrEF caused by ischemic cardiomyopathy,reduce the risk of MACE and number of hospitalization,with accurate short-term effect,which can be further promoted and applied in clinic.

关 键 词：沙库巴曲缬沙坦 射血分数降低心力衰竭 缺血性心肌病 

分 类 号：R541.6[医药卫生—心血管疾病]